Comparing the effectiveness of brolucizumab therapy alone versus that combined with subthreshold micropulse laser exposure in the treatment of diabetic macular edema

Authors

  • AO Giyasova Tashkent State Dental Institute, “SIHAT KO'Z” LTD Joint Venture
  • NR Yangieva Tashkent State Dental Institute

DOI:

https://doi.org/10.31288/oftalmolzh202321620

Keywords:

diabetic macular edema, anti-VEGF therapy, subthreshold micropulse laser exposure

Abstract

Background: Diabetic retinopathy (DR) is a major cause of blindness in working-age individuals in the developed countries. Studies have found that diabetic macular edema (DME) is a major cause of visual impairment in patients with diabetes mellitus (DM). Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of DME.

Material and Methods: Eighty-two patients (153 eyes) with DME were divided into two treatment groups. Group 1 (37 patients, 68 eyes) was treated with injections of the anti-VEGF agent brolucizumab according to the one plus pro re nata (PRN) regimen (once plus as needed) only, whereas group 2 (45 patients, 85 eyes) received a combination of “one plus PRN” brolucizumab therapy with subthreshold micropulse laser exposure (SMPLE). Before and after treatment, a comprehensive ophthalmological examination was performed, including the best-corrected visual acuity (BCVA) and the height of retinal edema in the central fovea as assessed by optical coherence tomography. The parameters were assessed at 1, 3, 6 and 12 months after treatment.

Results: The percentage of patients with no need for additional anti-VEGF injections was substantially higher in the combined therapy group than in the monotherapy group (68.5% versus 12%, respectively, p <0.001).

Conclusion: The combination treatment (intravitreal brolucizumab combined with SMPLE) for DME was effective in 68.5% of cases within 12 months. In this way, a steady resorption of DME is accomplished through antivasoproliferative and prolonged effects of brolucizumab and the SMPLE session.

References

Volodin PL, Ivanova EV., Khrisanfova ES. [Navigational technology of targeted topographically oriented laser coagulation in the treatment of focal diabetic macular edema: First clinical results]. Modern technologies in ophthalmology. 2018;1:65-68. Russian.

Bobykin EV. Modern approaches to the treatment of diabetic macular edema. Ophthalmosurgery. 2019;1:67-76. https://doi.org/10.25276/0235-4160-2019-1-67-76

Umanets NN, Rozanova Z A, Alzein M. [Combination of intravitreal injections of ranibizumab and selective laser coagulation of retinal pigment epithelium in the treatment of diabetic cystoid macular edema]. Oftalmol Zh. 2013;3:18-22. Russian. https://doi.org/10.31288/oftalmolzh201331822

Lipatov DV, Lyshkanets OI. [Intravitreal therapy of diabetic macular edema in Russia: the current state of the problem]. Bulletin of ophthalmology. 2019;135(4):128-39. Russian. https://doi.org/10.17116/oftalma2019135041128

Okhotsimskaya TD, Zaitseva OV. [Aflibercept in the treatment of retinal diseases. Review of clinical studies]. Russian Ophthalmological Journal. 2017;2S:103-111. https://doi.org/10.21516/2072-0076-2017-10-2-103-111

Diabetic Retinopathy Clinical Research Network (DRCR.net) Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009 Mar;127(3):245-51. https://doi.org/10.1001/archophthalmol.2008.610

Busch C, Fraser-Bell S, Zur D, et al.; International Retina Group. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetol. 2019;56(7):777-784. https://doi.org/10.1007/s00592-019-01310-z

Akkaya S, Açıkalın B, Doğan YE, Çoban F. Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. Int J Ophthalmol. 2020; 13(10): 1606-1611. https://doi.org/10.18240/ijo.2020.10.15

Wells JA, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022

Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye (Lond) 2017;31(2):342-345. https://doi.org/10.1038/eye.2016.233

Hodzic-Hadzibegovic D., Sander B.A., Monberg T.J. et al. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines. Acta Ophthalmol. 2018;96(3):267-278. https://doi.org/10.1111/aos.13638

Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022;238:157-172. https://doi.org/10.1016/j.ajo.2022.01.004

Fursova AZh, Derbeneva AS, Tarasov MS. Clinical efficacy of anti-angiogenic therapy for diabetic macular edema in real clinical practice (2-year results). Russian Ophthalmological Journal. 2021;14(2):42-9. https://doi.org/10.21516/2072-0076-2021-14-2-42-49

Early Treatment Diabetic Retinopathy Study research group. Early Treatment Diabetic Retinopathy Study (ETDRS). Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-806. https://doi.org/10.1001/archopht.1985.01050120030015

Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2129-2135. https://doi.org/10.1007/s00417-015-2965-7

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222. https://doi.org/10.1159/000458539

Pankratov MM. Pulsed delivery of laser energy in experimental thermal retinal photocoagulation. Proc Soc Photo Opt Instrum Eng. 1990;1202:205-13. https://doi.org/10.1117/12.17626

Moisseiev E, Abbassi S, Thinda S, Yoon J, Yiu G, Morse LS. Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema. Eur J Ophthalmol. 2018;28(1):68-73. https://doi.org/10.5301/ejo.5001000

Su D, Hubschman JP. A review of subthreshold micropulse laser and recent advances in retinal laser technology. Ophthalmol Ther. 2017;6(1):1-6. https://doi.org/10.1007/s40123-017-0077-7

Wu Y, Ai P, Ai ZS, Xu GT. Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: a Bayesian network meta-analysis. Biomed Pharmacother. 2018;97:293-299. https://doi.org/10.1016/j.biopha.2017.10.078

Fedchenko SA, Zadorozhnyy OS, Molchaniuk NI, Korol AR. Comparing ultrastructural changes in the rabbit chorioretinal complex after 577-nm and 532-nm laser photocoagulation. J Ophthalmol (Ukraine). 2017;6:56-71. https://doi.org/10.31288/oftalmolzh201765671

Published

2023-04-25

How to Cite

1.
Giyasova A, Yangieva N. Comparing the effectiveness of brolucizumab therapy alone versus that combined with subthreshold micropulse laser exposure in the treatment of diabetic macular edema. J.ophthalmol. (Ukraine) [Internet]. 2023 Apr. 25 [cited 2024 Apr. 22];(2):16-20. Available from: https://ua.ozhurnal.com/index.php/files/article/view/21

Issue

Section

Clinical Ophthalmology